Drugs / Roledumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02287896 | Apr 2014 → Sep 2017 | Rh isoimmunization | LFB | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Roledumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02287896 ↗ |
| Action | Inhibit | “Blood group Rh(D) polypeptide inhibitor” CHEMBL1743065 ↗ |
| Modality | Monoclonal antibody | “a Fully Human Recombinant Monoclonal Anti-RhD Antibody” NCT02287896 ↗ |
| Route | Intramuscular | “a single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.” NCT02287896 ↗ |
| Target | RHD | “Blood group Rh(D) polypeptide inhibitor” CHEMBL1743065 ↗ |